Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prescient TherapeuticsFRA:UDD +5.00% Cash Ratio is 7.65 as of Dec. 2025, which is 42% below its 10-year median of 13.14. The stock has 3 warning signs investors should review. Among 1,384 Biotechnology companies, Prescient Therapeutics ranks better than 73.27% on this metric.
Prescient Therapeutics has a Cash Ratio of 7.65. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Prescient Therapeutics's Cash Ratio or its related term are showing as below:
FRA:UDD'
s Cash Ratio Range Over the Past 10 Years
Min: 2.19 Med: 13.14 Max: 76.87
Current: 7.64
During the past 13 years, Prescient Therapeutics's highest Cash Ratio was 76.87. The lowest was 2.19. And the median was 13.14.
FRA:UDD's Cash Ratio is ranked better than 73.27% of 1384
companies
in the Biotechnology industry
Industry Median: 2.93
vs FRA:UDD: 7.64
Prescient Therapeutics (FRA:UDD) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UDD vs VRTX, REGN, RVMD: Cash Ratio Comparison
For the Biotechnology subindustry, Prescient Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prescient Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Prescient Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prescient Therapeutics (FRA:UDD) has a Cash Ratio of 7.65 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Prescient Therapeutics and its competitors. This is 42% below median its historical median of 13.14. Over the past decade, Prescient Therapeutics' Cash Ratio has ranged from 2.19 to 76.87. According to the industry distribution chart, Prescient Therapeutics ranks #370 out of 1384 companies in the Biotechnology industry, placing it in the top 26.7%.
Is Prescient Therapeutics' Cash Ratio too high?
Prescient Therapeutics' current Cash Ratio of 7.65 is 42% below median its 10-year median of 13.14. Over the past 10 years, this metric has ranged from a low of 2.19 to a high of 76.87. The Biotechnology industry median Cash Ratio is 2.93. Prescient Therapeutics' value of 7.65 is 161.1% above this industry median. Based on the distribution chart, Prescient Therapeutics ranks #370 out of 1384 companies in the Biotechnology industry, which is above the industry midpoint.
How does Prescient Therapeutics' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Prescient Therapeutics ranks #370 out of 1384 companies for Cash Ratio. This puts Prescient Therapeutics in the upper half of its industry. The industry median Cash Ratio is 2.93. Prescient Therapeutics' value of 7.65 is 161.1% above this benchmark. Historically, Prescient Therapeutics' own Cash Ratio has ranged from 2.19 to 76.87 over the past decade. While the company's 10-year median is 13.14 vs. the industry median of 2.93, Prescient Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prescient Therapeutics's current Cash Ratio of 7.65 is 161.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Prescient Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prescient Therapeutics's current Cash Ratio is 7.65, which is 42% below median its own 10-year median of 13.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prescient Therapeutics stock overvalued right now?
Prescient Therapeutics (FRA:UDD) has a current Cash Ratio of 7.65. The current Cash Ratio is 7.65, which is 42% below median its 10-year median of 13.14 and 161.1% above the Biotechnology industry median of 2.93. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Prescient Therapeutics (FRA:UDD), the current Cash Ratio is 7.65 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UDD has been successfully added to your 
